{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:39:49Z","timestamp":1793353189591,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","cysticfibrosisjournal.com","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jcf.2024.10.006","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T18:37:12Z","timestamp":1730313432000},"page":"135-141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Factors associated with prescription of elexacaftor\/tezacaftor\/ivacaftor among people with cystic fibrosis aged 12 years or older with at least one F508del allele"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1793-2173","authenticated-orcid":false,"given":"Georgene E","family":"Hergenroeder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6396-2379","authenticated-orcid":false,"given":"Jonathan V","family":"Todd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh S.","family":"Ostrenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher H","family":"Goss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2407-7374","authenticated-orcid":false,"given":"Raksha","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6346-8140","authenticated-orcid":false,"given":"Wayne","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory S.","family":"Sawicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8473-3767","authenticated-orcid":false,"given":"Michael S","family":"Schechter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A","family":"Cromwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4431-0644","authenticated-orcid":false,"given":"Clement L","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2024.10.006_bib0001","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMra2216474","volume":"389","author":"Grasemann","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2024.10.006_bib0002","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2024.10.006_bib0003","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2024.10.006_bib0004","first-page":"281","article-title":"CFTR modulators: transformative therapies for cystic fibrosis","volume":"27","author":"Dwight","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.jcf.2024.10.006_bib0005","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1055\/s-0042-1758851","article-title":"CFTR Modulators: Current Status and Evolving Knowledge","volume":"44","author":"Regard","year":"2023","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.10.006_bib0006","unstructured":"Cystic fibrosis foundation patient registry 2022 annual data report. Bethesda, Maryland; 2023."},{"key":"10.1016\/j.jcf.2024.10.006_bib0007","first-page":"1146","volume":"12","author":"Sawicki","year":"2015"},{"key":"10.1016\/j.jcf.2024.10.006_bib0008","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jcf.2018.08.007","article-title":"Rate and predictors of prescription of lumacaftor - Ivacaftor in the 18 months following approval in the United States","volume":"17","author":"Sawicki","year":"2018","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.10.006_bib0009","doi-asserted-by":"crossref","first-page":"S205","DOI":"10.1016\/S1569-1993(23)01328-0","article-title":"Black and Hispanic people with cystic fibrosis (PwCF) and PwCF with high lung function are less likely to be prescribed elexacaftortezacaftor-ivacaftor despite having an eligible genotype","volume":"22","author":"Hergenroeder JT","year":"2023","journal-title":"J Cystic Fibros"},{"key":"10.1016\/j.jcf.2024.10.006_bib0010","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.27040","article-title":"Disparities in elexacaftor\/tezacaftor\/ivacaftor initiation in the US cystic fibrosis population","author":"Jordan","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2024.10.006_bib0011","first-page":"1173","volume":"13","author":"Knapp","year":"2016"},{"key":"10.1016\/j.jcf.2024.10.006_bib0012","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jcf.2023.02.009","article-title":"Cystic fibrosis prevalence in the United States and participation in the Cystic Fibrosis Foundation Patient Registry in 2020","volume":"22","author":"Cromwell","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.10.006_bib0013","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"issue":"Suppl 1","key":"10.1016\/j.jcf.2024.10.006_bib0014","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1097\/00005176-198400031-00016","article-title":"Improved prognosis in CF patients with normal fat absorption","volume":"3","author":"Corey","year":"1984","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jcf.2024.10.006_bib0015","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jcf.2013.02.008","article-title":"Update on cystic fibrosis-related diabetes","volume":"12","author":"Kelly","year":"2013","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.10.006_bib0016","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1164\/rccm.200304-505SO","article-title":"Pathophysiology and management of pulmonary infections in cystic fibrosis","volume":"168","author":"Gibson","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.10.006_bib0017","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1001\/jama.2010.791","article-title":"Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis","volume":"303","author":"Dasenbrook","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jcf.2024.10.006_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2024.03.013","article-title":"The impact of switching to race-neutral reference equations on FEV(1) percent predicted among people with cystic fibrosis(","author":"Rosenfeld","year":"2024","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324018010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324018010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T22:11:42Z","timestamp":1738275102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324018010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1569199324018010"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.10.006","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors associated with prescription of elexacaftor\/tezacaftor\/ivacaftor among people with cystic fibrosis aged 12 years or older with at least one F508del allele","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}